Chronic Myelomonocytic Leukemia (CMML) Specialist Diagnosis & Advanced Care Access

Chronic Myelomonocytic Leukemia (CMML) is a rare haematological cancer that has features of both myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN) — hence its classification as an MDS/MPN overlap entity. Its defining feature is a persistently elevated monocyte count (a type of white blood cell) in the blood. Unlike CML (which is driven by a single BCR-ABL1 mutation), CMML has a complex molecular landscape with multiple cooperating mutations (TET2, ASXL1, SRSF2). It differs from MDS in having persistent monocytosis rather than just bone marrow failure, and from MPN in having significant dysplasia alongside the excess monocyte production.

Monocyte elevations can be reactive (from infections, autoimmune diseases, inflammatory conditions) or clonal (as in CMML). Distinguishing clonal from reactive monocytosis requires blood count monitoring for persistence over >3 months, bone marrow biopsy, and NGS mutation testing. A specialised blood test called 'classical monocyte fraction' by flow cytometry — which measures the proportion of CD14+CD16-classical monocytes — is very useful: values >94% strongly support clonal CMML rather than reactive monocytosis. BCR-ABL1 PCR is also required to exclude CML with monocytosis.

CMML is classified by the percentage of blast cells (immature leukaemia cells) in the blood and bone marrow: CMML-0 has fewer than 2% blasts in the blood and fewer than 5% in the marrow; CMML-1 has 2–4% in blood and 5–9% in marrow; CMML-2 has 5–19% in blood and 10–19% in marrow. Higher blast percentages indicate greater disease burden and higher risk of transformation to acute myeloid leukaemia (AML). CMML-2 has the highest transformation risk and generally requires active treatment. The classification is important for treatment decisions but is considered alongside molecular risk factors (ASXL1 mutation, karyotype) in modern risk scoring.

ASXL1 mutations are the most important single adverse molecular marker in CMML, present in approximately 40% of patients. ASXL1 is a chromatin regulator gene; loss of its function disrupts normal blood cell differentiation and epigenetic control. ASXL1-mutated CMML is associated with significantly shorter overall survival, higher AML transformation risk, and inferior outcomes even after allo-SCT compared to ASXL1 wild-type CMML. Critically, ASXL1 mutation in a patient with otherwise low-risk features (CMML-0, normal karyotype) still substantially increases the effective risk — making molecular profiling essential for all CMML patients before treatment decisions are made.

Azacitidine is a hypomethylating agent (HMA) — it inhibits the enzyme DNMT (DNA methyltransferase), reducing abnormal epigenetic silencing of tumour suppressor and differentiation genes in CMML cells. It is the most commonly used active medical therapy for CMML requiring treatment, given as a subcutaneous or intravenous injection on days 1–7 of a 28-day cycle. Azacitidine improves blood counts (reducing transfusion dependence), reduces blast percentage, and controls symptoms in approximately 40–50% of patients, though complete remissions are uncommon. It does not permanently eliminate the CMML clone and responses eventually wane. Azacitidine is also used as a bridge to allo-SCT in patients being prepared for transplant.

Allo-SCT is the only treatment with established potential to alter the natural history of CMML and achieve long-term disease-free survival. It is recommended for patients with CMML-1 (especially with ASXL1 mutation or adverse karyotype) and CMML-2, who are up to approximately 70–75 years of age with adequate performance status and organ function. Even older patients may be eligible with reduced-intensity conditioning regimens. The key requirements are: adequate heart, lung, kidney, and liver function; performance status ECOG ≤2; and availability of a suitable donor (sibling, matched unrelated, or haploidentical). Transplant eligibility should be assessed at diagnosis, not deferred until HMA failure.

AML (acute myeloid leukaemia) transformation in CMML means the disease has progressed to a blast percentage of ≥20% in the blood or bone marrow — meeting the threshold for acute leukaemia. At this point, the condition is reclassified as 'AML arising from CMML' (or 'AML with myelodysplasia-related changes'). This transformation occurs in approximately 15–20% of CMML patients at 3 years and carries a significantly worse prognosis than de novo AML, as the cells are typically resistant to standard induction chemotherapy. Management at this point requires urgent specialist input — CPX-351 (for fit patients), HMA + venetoclax (for less fit patients), and urgent allo-SCT planning for those in remission.

Yes — autoimmune and inflammatory manifestations are more common in CMML than in most haematological malignancies, occurring in approximately 20–30% of patients. These can include skin rashes (Sweet's syndrome, vasculitic rashes), inflammatory arthritis, pleuritis, pericarditis, and peripheral neuropathy. The clonal monocytes and dysregulated immune environment of CMML drive these inflammatory complications. They may precede, coincide with, or emerge after the CMML diagnosis. Management typically involves corticosteroids and sometimes disease-modifying agents, in coordination between haematology and rheumatology.

Yes. CancerFax supports patients with CMML by reviewing bone marrow biopsy reports, NGS mutation panels, and cytogenetic results, facilitating specialist haematology second opinions on CMML risk stratification and treatment planning, assisting with transplant eligibility assessment and donor identification, identifying clinical trial access (venetoclax combinations, IDH inhibitor programmes, MEK inhibitor studies), and coordinating specialist MDS/CMML consultations at leading haematology centres in India, China, and internationally. Please share your diagnostic reports via the CancerFax portal or contact our team to begin.